Zoledronic acid does not affect insulin resistance in men receiving androgen deprivation therapy: a prespecified secondary analysis of a randomised controlled trial.
Journal Information
Full Title: Ther Adv Endocrinol Metab
Abbreviation: Ther Adv Endocrinol Metab
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Subject Category: Endocrinology & Metabolism
Available in Europe PMC: Yes
Available in PMC: Yes
PDF Available: No
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Conflict of interest statement: Novartis Pharmaceuticals Australia provided ampoules of zoledronic acid (Aclasta®) and matching placebo without cost. Novartis was not involved in the trial design and had no role in the trial design, execution, data analysis, interpretation of the results or writing of the manuscript. The company did not provide financial or any other support beyond provision of drug and placebo."
"Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The study was funded by an Australian Government National Health and Medical Research Council (NHMRC) Project Grant (#1062073). Ada Cheung was supported by a NHMRC Medical and Dental Postgraduate Research Scholarship (#1017233), NHMRC Early Career Fellowship (#1143333) and an Endocrine Society of Australia Postdoctoral Award. Mathis Grossmann was supported by a NHMRC Career Development Fellowship (#1024139)."
"Trial Registration Number: [ClinicalTrials.gov identifier: NCT01006395]."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025